Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles

Borisov, N.; Sergeeva, A.; Suntsova, M.; Raevskiy, M.; Gaifullin, N.; Mendeleeva, L.; Gudkov, A.; Nareiko, M.; Garazha, A.; Tkachev, V.; Li Xinmin; Sorokin, M.; Surin, V.; Buzdin, A.

Авторы: Borisov Nicolas, Sergeeva Anna, Suntsova Maria, Raevskiy Mikhail, Gaifullin Nurshat, Mendeleeva Larisa, Gudkov Alexander, Nareiko Maria, Garazha Andrey, Tkachev Victor, Li Xinmin, Sorokin Maxim, Surin Vadim, Buzdin Anton
Журнал: Frontiers in oncology
Том: 11
Номер: 4
Год издания: 2021
Издательство: Frontiers Research Foundation
Местоположение издательства: Switzerland
Номер статьи: 652063
DOI: 10.3389/fonc.2021.652063
Аннотация: Multiple myeloma (MM) affects ~500,000 people and results in ~100,000 deaths annually, being currently considered treatable but incurable. There are several MM chemotherapy treatment regimens, among which eleven include bortezomib, a proteasome-targeted drug. MM patients respond differently to bortezomib, and new prognostic biomarkers are needed to personalize treatments. However, there is a shortage of clinically annotated MM molecular data that could be used to establish novel molecular diagnostics. We report new RNA sequencing profiles for 53 MM patients annotated with responses on two similar chemotherapy regimens: bortezomib, doxorubicin, dexamethasone (PAD), and bortezomib, cyclophosphamide, dexamethasone (VCD), or with responses to their combinations. Fourteen patients received both PAD and VCD; six received only PAD, and 33 received only VCD. We compared profiles for the good and poor responders and found five genes commonly regulated here and in the previous datasets for other bortezomib regimens (all upregulated in the good responders): FGFR3, MAF, IGHA2, IGHV1-69, and GRB14. Four of these genes are linked with known immunoglobulin locus rearrangements. We then used five machine learning (ML) methods to build a classifier distinguishing good and poor responders for two cohorts: PAD + VCD (53 patients), and separately VCD (47 patients). We showed that the application of FloWPS dynamic data trimming was beneficial for all ML methods tested in both cohorts, and also in the previous MM bortezomib datasets. However, the ML models build for the different datasets did not allow cross-transferring, which can be due to different treatment regimens, experimental profiling methods, and MM heterogeneity.
Добавил в систему: Гайфуллин Нуршат Минуллаевич

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ЦЭМИ РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ЦЭМИ РАН

Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profilesстатья

Прикрепленные файлы